COMP <GO>
IDXX vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
IDEXX Laboratories Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IDXX 9
— ABBV 6
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: IDXX
LAST: $551.21 (-4.30%) • MKT CAP: $45.38B
options-implied-move
6.50%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.80% | 70.20% | -8.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.60% | 29.00% | +0.60 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.1x | 33.3x | -2.20 | IDXX | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 3.47% | -1.14 | ABBV | /fcf-yield <GO> |
| Operating Margin | 31.60% | 24.60% | +7.00 | IDXX | /operating-margins <GO> |
| Net Profit Margin | 24.60% | 6.90% | +17.70 | IDXX | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 8.60% | +1.80 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.99 | 5.33 | +15.66 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.50% | 7.40% | -0.90 | IDXX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 72.8 | -20.39 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.15 | -0.26 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.8x | 113.1x | -73.30 | IDXX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.38B | $513.86B | -$468.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXX REV | ABBV REV | IDXX GROSS % | ABBV GROSS % | IDXX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.30B | $61.16B | 61.8% | 70.2% | $1.06B | $17.82B |
| FY 2024 | $3.90B | $56.33B | 61.0% | 70.0% | $808.1M | $17.83B |
| FY 2023 | $3.66B | $54.32B | 44.0% | 44.0% | $741.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXX // BETA 0.89
ABBV // BETA 1.15